Evidence map›Paper›PMID 31253132›Full record

ArticleBMC cancer2019

Biological molecular layer classification of muscle-invasive bladder cancer opens new treatment opportunities.

Lucía Trilla-Fuertes, Angelo Gámez-Pozo, Guillermo Prado-Vázquez, Andrea Zapater-Moros, Mariana Díaz-Almirón, Jorge M Arevalillo, María Ferrer-Gómez, Hilario Navarro, Paloma Maín, Enrique Espinosa and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Clinical and therapeutic implications of sex steroid hormone receptor status in urothelial bladder cancer.Indian journal of urology : IJU : journal of the Urological Society of India
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Lucía Trilla-FuertesBiomedica Molecular Medicine SL, Madrid, Spain.
Angelo Gámez-PozoBiomedica Molecular Medicine SL, Madrid, Spain.
Guillermo Prado-VázquezBiomedica Molecular Medicine SL, Madrid, Spain.
Andrea Zapater-MorosBiomedica Molecular Medicine SL, Madrid, Spain.
Mariana Díaz-AlmirónBiostatistics Unit, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
Jorge M ArevalilloDepartment of Statistics, Operational Research and Numerical Analysis, Universidad Nacional de Educación a Distancia (UNED), Madrid, Spain.
María Ferrer-GómezMolecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
Hilario NavarroDepartment of Statistics, Operational Research and Numerical Analysis, Universidad Nacional de Educación a Distancia (UNED), Madrid, Spain.
Paloma MaínDepartment of Statistics and Operations Research, Faculty of Mathematics, Complutense University of Madrid, Madrid, Spain.
Enrique EspinosaServicio de Oncología Médica, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
Álvaro PintoServicio de Oncología Médica, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
Juan Ángel Fresno VaraMolecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain. juanangel.fresno@salud.madrid.org.ORCID http://orcid.org/0000-0003-1527-1252
Hospital Universitario La Paz · ESUniversidad Nacional de Educación a Distancia · ESUniversidad Complutense de Madrid · ES

Funding

Consejería de Educación, Juventud y Deporte, Comunidad de Madrid IND2017/BMD778Instituto de Salud Carlos III (ES) PI15/01310Ministerio de Economía y Competitividad (ES) DI-15-07614
6 · The paper itself

Abstract

backgroundMuscle-invasive bladder tumors are associated with a high risk of relapse and metastasis even after neoadjuvant chemotherapy and radical cystectomy. Therefore, further therapeutic options are needed and molecular characterization of the disease may help to identify new targets. The aim of this study was to characterize muscle-invasive bladder tumors at the molecular level using computational analyses.

methodsThe TCGA cohort of muscle-invasive bladder cancer patients was used to describe these tumors. Probabilistic graphical models, layer analyses based on sparse k-means coupled with Consensus Cluster, and Flux Balance Analysis were applied to characterize muscle-invasive bladder tumors at a functional level.

resultsLuminal and Basal groups were identified, and an immune molecular layer with independent value was also described. Luminal tumors showed decreased activity in the nodes of epidermis development and extracellular matrix, and increased activity in the node of steroid metabolism leading to a higher expression of the androgen receptor. This fact points to the androgen receptor as a therapeutic target in this group. Basal tumors were highly proliferative according to Flux Balance Analysis, which makes these tumors good candidates for neoadjuvant chemotherapy. The Immune-high group showed a higher degree of expression of immune biomarkers, suggesting that this group may benefit from immune therapy.

conclusionsOur approach, based on layer analyses, established a Luminal group candidate for therapy with androgen receptor inhibitors, a proliferative Basal group which seems to be a good candidate for chemotherapy, and an immune-high group candidate for immunotherapy.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Transitional CellExtracellular MatrixFemaleGene Expression ProfilingHumansMaleMetabolic Networks and PathwaysMiddle AgedNeoplasm InvasivenessReceptors, AndrogenUrinary Bladder NeoplasmsBiomarkers, TumorReceptors, AndrogenAndrogen receptorImmune statusMolecular subtypesMuscle-invasive bladder cancerPersonalized medicine

Identifiers

PMID31253132
PMCPMC6599340
OpenAlexW2956097522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.